какво е revlimid за?
multiple myeloma revlimid as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation revlimid as combination therapy with dexamethasone or bortezomib and dexamethasone or melphalan and prednisone see section 4 2 is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy myelodysplastic syndromes revlimid as monotherapy is indicated for the treatment of adult patients with transfusion dependent anemia due to low or intermediate 1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate mantle cell lymphoma revlimid as monotherapy is indicated for the treatment of adult pa